-
A Phase 2 Open-Label Multicenter Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6
This is a Phase 2, global, multicenter, open-label, cohort study designed to evaluate the antitumor activity, safety and tolerability, HRQoL, PK, and pharmacodynamics of ALKS ... -
A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
This is a randomized phase II adjuvant study for women and men with Stage I HER2-positive invasive breast cancer. At least 500 eligible patients will ... -
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) [EA6192]
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that ... -
Interventional randomized double-blind parallel-group placebo-controlled multi-centre study to assess the efficacy safety and tolerability of Lu AF82422 in patients with Multiple System Atrophy
This is a phase II, interventional, randomized, double-blind, parallel-group, placebocontrolled, multi-centre study of the efficacy (slowing disease progression), safety, and tolerability of Lu AF82422 in ... -
A randomized double-blind placebo-controlled study of ALPN-101 in systemic lupus erythematosus.
Subjects will be evaluated during a screening period of 42 days. Screening laboratory evaluations and disease activity assessments will be performed by the Investigator and ... -
ACNS2021: A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Site for This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction ... -
A Phase 2a Multicenter Randomized Doubleblind Study Evaluating the Efficacy and Safety of Subcutaneously Administered combination therapy in Improving the Signs and Symptoms in Participants with Active Psoriatic Arthritis.
This is a Phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept (POC) clinical study designed to evaluate the efficacy and safety of combination therapy with ... -
A Follow-Up Open-Label Research Evaluation of Sustained Treatment with Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)
This is an open-label study of CK-3773274 in patients with HCM. The treatment duration is anticipated to be multiple years, concluding when marketing authorization is ... -
CBYL719F12201: EPIK-P2 Phase II double-blind study w/ upfront 16-week randomized placebo-controlled period to assess efficacy safety & pharmacokinetics of alpelisib (BYL719) in pediatric & adult patients w/ PIK3CA-related overgrowth spectrum (PROS)
This study will be the first prospective study of alpelisib in participants with PROS. Local overgrowth or hemihypertrophy, mostly progressive, is the most frequently observed ... -
Site for Biomarker and Edema Attenuation in IntraCerebral hemorrhage (BEACH)
Site for This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH ...